UK national priority COVID-19 trial now recruiting patients
The PRINCIPLE trial aims to evaluate therapeutics that could slow the progression of COVID-19 symptoms in patients most at risk of complications.
List view / Grid view
The PRINCIPLE trial aims to evaluate therapeutics that could slow the progression of COVID-19 symptoms in patients most at risk of complications.
By attaching cyclic peptides to modified liposomes, researchers have created a potential form of drug delivery able to cross the blood-brain barrier.
RedHill Biopharma has submitted its Investigational New Drug application for its drug opaganib, for the treatment of COVID-19, to the FDA.
Whitty will take a leave of absence, effective today, to co-lead a global effort by the World Health Organization (WHO) to accelerate the development of a COVID-19 vaccine.
The FDA has said that Amneal Pharmaceuticals is recalling three lots of nizatidine oral solution at the consumer level due to potential NDMA contamination.
Novo Nordisk has set up a programme to allow patients in the US experiencing financial hardship because of COVID-19 to receive free insulin for 90 days.
The generic Proventil HFA (albuterol sulfate) metered dose inhaler has been approved for the prevention of bronchospasm in patients four years of age and older.
An open letter from aid organisations and academics has called on the UK government to stipulate conditions for pharmaceutical companies using public funding for COVID-19 vaccines.
Teva has informed the MHRA that the GTIN number found on a batch of levofloxacin tablets is incorrect, prompting the Medicines Defect Information alert.
FUJIFILM intends to accelerate production of Avigan to 100,000 treatment courses per month by July and up to 300,000 by September 2020 to meet demand for possible use treating COVID-19.
The enterprise announced its drug OLUMIANT® (baricitinib) and an investigational antibody will enter clinical trials in US COVID-19 patients later this month.
A new report has revealed that Germany is set to lead the aseptic sampling market in Europe, contributing $35.7 million to the market until 2025.
The developers of the novel formulation, containing the cannabinoids CBDV and CBGA, now intend to test the clinical safety and efficacy of its anti-cancer activity.
Sanofi will provide its S protein antigen and GSK will contribute its adjuvant technology in a partnership to develop a COVID-19 vaccine.
Despite some positive results from clinical trials for COVID-19 treatments, separate tests of the same therapies have not met primary endpoints.